Glucagon-like peptide 1 in patients with type 2 diabetes mellitus on insulin therapy
Insulin administration is one of the ways to intensify glucose-lowering therapy in type 2 diabetes mellitus (T2DM). The postprandial dynamics of glucagon-like peptide‑1 (GLP-1) in patients with different secretory activity of pancreatic β-cells in patients with T2DM has not been adequately studied.
Aim is to evaluate the stimulated secretion of GLP-1 and C-peptide in patients with T2DM on insulin therapy.
Material and methods. In 108 patients with T2DM on insulin therapy, residual insulin secretion was determined by C-peptide. In patients with different secretory activity of β-cells of the pancreas in a test with “standard breakfast” the degree of changes in C-peptide and GLP-1 at 30 min point was measured, the results were compared with those of healthy individuals.
Results. The basal level of GLP-1 in patients with T2DM was lower than in healthy individuals and was not associated with the basal level of C-peptide. The increase in the level of GLP-1 after standard breakfast in patients with T2DM and signs of secretory deficiency (C-peptide <1.1 ng/ml) was significantly higher than in patients with an increased basal level of C-peptide (>4.4 ng/ml) (p<0.001).
Keywords:type 2 diabetes mellitus; insulin therapy; C-peptide; glucagon-like peptide 1
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Lisker A.V., Semikova G.V., Volkova A.R. Glucagon-like peptide‑1 in patients with type 2 diabetes mellitus on insulin therapy. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022; 11 (2): 9–13. DOI: https://doi.org/10.33029/2304-9529-2022-11-2-9-13 (in Russian)
1. Ametov A.S. Iinsulin therapy. Role and place in management of type 2 diabetes mellitus. RMZh [Russian Medical Journal]. 2014; 22 (13): 970–3. (in Russian)
2. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A. Yu. 10th Edition, Moscow, 2021. (in Russian)
3. Dedov I.I., Shestakova M.V., Vikulova O.K. National register of diabetes mellitus in Russian Federation. Sakharniy diabet [Diabetes Mellitus]. 2015; 18 (3): 5–22. DOI: https://doi.org/10.14341/DM201535-22 (in Russian)
4. Dedov I.I., Kalashnikova M.F., Belousov D.Y., et al. Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of рharmacoepidemiological study (FORSIGHT-DM2). Sakharniy diabet [Diabetes Mellitus]. 2016; 19 (6): 443–46. DOI: https://doi.org/10.14341/DM8146 (in Russian)
5. Nauck M.A., Meier J.J. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018; 20 (suppl 1): 5–21.
6. Nauck M.A., Meier J.J. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016; 4 (6): 525–36.
7. Stanchev P., Orbetzova M., Terzieva D. Serum levels of incretin hormones – GLP-1 and GIP in patients with type 1 diabetes mellitus. Folia Med (Plovdiv). 2019; 61 (1): 76–83.
8. Katra B., Fedak D., Matejko B. The enteroendocrine-osseous axis in patients with long-term type 1 diabetes mellitus. Bone. 2021; 153: 116105.
9. Chia C.W., Egan J.M. Incretins in obesity and diabetes. Ann N Y Acad Sci. 2020; 1461 (1): 104–26.
10. Wysham C., Shubrook J. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications. Postgrad Med. 2020; 132 (8): 676–86.
11. Jirapinyo P., Jin D.X., Qazi T.A. Meta-analysis of GLP-1 after Roux-En-Y gastric bypass: impact of surgical technique and measurement strategy. Obes Surg. 2018; 28 (3): 615–26. DOI: https://doi.org/10.1007/s11695-017-2913-1
12. Hong J.H., Kim D.H., Lee M.K. Glucolipotoxicity and GLP-1 secretion. BMJ Open Diabetes Res Care. 2021; 9 (1): e001905. DOI: https://doi.org/10.1136/bmjdrc-2020-001905